Detalhe da pesquisa
1.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944848
2.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112166
3.
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncol
; 14(12): 1183-92, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24095300